Arrhythmia Disorders News

SGLT2 inhibition was associated with reduced 5-year risk for stroke among patients with concomitant atrial fibrillation and diabetes, according to a study in the Journal of the American Heart Association.

A device to move the esophagus away from the catheter tip during ablation for atrial fibrillation reduced esophageal injury during procedures, according to the results of the EASY AF study presented at Heart Rhythm 2023.

In adults with scar-related ventricular tachycardia, a strategy of ventricular tachycardia ablation plus implantation of a subcutaneous implantable cardioverter defibrillator led to better outcomes than use of a transvenous ICD, data show.

Bristol Myers Squibb in collaboration with Janssen Pharmaceuticals announced all three prospective antithrombotic indications for milvexian have received fast track designation from the FDA.

Use of a third-party universal remote monitoring platform was linked to better survival and hospitalization outcomes than conventional remote monitoring or no monitoring in patients with implanted cardiac devices, researchers reported.

People with a high level of neuroticism were more likely to develop atrial fibrillation, and to do so at a younger age, compared with people with lower levels, according to a study presented at Heart Rhythm 2023.

In patients with acute stroke and atrial fibrillation, oral anticoagulation therapy may be administered within 48 hours after stroke when appropriate or indicated, researchers reported.

In the EU-PORIA real-world registry of patients with atrial fibrillation who underwent pulsed field ablation, most patients did not have recurrence at 1 year and the learning curve for operators was quick.

In patients with an implantable cardioverter defibrillator, those who had transvenous leads had worse outcomes related to tricuspid regurgitation than those who had subcutaneous leads, according to new data from the ATLAS trial.

A dual-chamber leadless pacemaker was successfully implanted in most patients and met its 3-month safety and efficacy performance goals, according to the results of the Aveir DR i2i investigational device exemption trial.